New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
98.9% of patients treated with Xoft remained
recurrence-free at a median follow-up of 7.6 years, according to recent study published
in Journal of Contemporary Brachytherapy
NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions, today
announced compelling new long-term real-world research confirms Xoft Skin eBx
is as safe and effective as Mohs surgery for the treatment of non-melanoma skin
cancer (NMSC). In the longest-term study of Xoft Skin eBx to-date, published in
the Journalof Contemporary Brachytherapy, 98.9% of patients remained
recurrence-free at a median follow-up of 7.6 years.
“NMSC is the most commonly diagnosed cancer in the U.S. and
its incidence continues to grow worldwide.[1],[2]
With a disease this prevalent, clinicians need proven solutions and treatment
plans as individualized as each patient,” said Dana Brown, President and CEO of
iCAD, Inc. “Xoft Skin eBx is changing the face of non-melanoma skin cancer
treatment. This study adds to the body of clinical evidence that puts Xoft Skin
eBx on par with Mohs surgery with regards to safety, efficacy, and recurrence
rates, but with fewer side effects and more comfort and convenience for
patients. Xoft offers the potential to positively impact the lives of cancer
patients and the providers who care for them on a global scale, and we are
pleased to see the body of evidence supporting this technology continue to grow
with the publication of this study.”
Xoft Skin eBx offers a painless, noninvasive NMSC
treatment approach that precisely targets cancer cells, while sparing healthy
tissue. Using a small surface applicator placed on the skin, Xoft Skin eBx
targets cancer directly over a short series of office visits lasting a few
minutes each. The high dose, low energy treatment allows medical personnel to
remain in the room and enables patients to return to normal daily activities
immediately, with no downtime – maximizing outcomes and minimizing side effects
for patients.
The long-term real-world study evaluated 180 patients
with 182 NMSC lesions treated with Xoft Skin eBx at four study centers in
Northern and Southern California. With a recurrence rate of 1.1% at a mean
follow up of 7.5 years, researchers concluded Xoft Skin eBx is safe and
effective, showing excellent long-term local control and minimal long-term
toxicities.
“Because non-melanoma skin cancer is typically caused by sun
exposure, it inherently strikes in some of the most visible places on the body,
such as the face, scalp, nose, ears, arms, and legs. Unfortunately, these areas
can also be some of the toughest places to remove lesions surgically. And for
some patients, surgery is not an option or a preference,” said Stephen Doggett,
MD, FACR, Radiation Oncologist, Aegis Oncology. “Our study confirms that Xoft
Skin eBx offers a safe and effective treatment option for NMSC that is as
effective as Mohs surgery, but with fewer side effects.”
Xoft Skin eBx is particularly ideal in treating anatomically
challenging locations, as well as areas prone to difficulties in wound healing,
making it a viable option for patients who are not surgical candidates due to
medical comorbidities or other health issues. Other skin conditions such as
keloids are also suitable for treatment with skin eBx.
“Xoft skin eBx arms clinicians with a safe and effective
alternative to surgery that can be seamlessly integrated in virtually any
clinical setting. This comprehensive, end-to-end solution is supported by a
full-service oncology program, offering the flexibility and simplicity
clinicians need and the comfort and convenience patients deserve. Xoft offers a
versatile tool in the toolbox that is tough on tumors but gentle on patients, and
we are pleased to provide this clinically proven treatment to facilities and
patients worldwide,” added Ms. Brown.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is a global medical
technology leader providing innovative cancer detection and therapy solutions.
For more information, visit www.icadmed.com.
Forward-Looking Statements
Certain statements contained in this News Release
constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements about the
expansion of access to the Company’s products, improvement of performance,
acceleration of adoption, expected benefits of ProFound AI®, the benefits of the
Company’s products, and future prospects for the Company’s technology platforms
and products. Such forward-looking statements involve a number of known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance, or achievements of the Company to be materially different
from any future results, performance, or achievements expressed or implied by
such forward-looking statements. Such factors include, but are not limited, to
the Company’s ability to achieve business and strategic objectives, the
willingness of patients to undergo mammography screening in light of risks of
potential exposure to Covid-19, whether mammography screening will be treated
as an essential procedure, whether ProFound AI will improve reading efficiency,
improve specificity and sensitivity, reduce false positives and otherwise prove
to be more beneficial for patients and clinicians, the impact of supply and
manufacturing constraints or difficulties on our ability to fulfill our orders,
uncertainty of future sales levels, to defend itself in litigation matters,
protection of patents and other proprietary rights, product market acceptance,
possible technological obsolescence of products, increased competition,
government regulation, changes in Medicare or other reimbursement policies,
risks relating to our existing and future debt obligations, competitive
factors, the effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company’s filings with the Securities
and Exchange Commission. The words “believe,” “demonstrate,” “intend,”
“expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and
similar expressions identify forward-looking statements. Readers are cautioned
not to place undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no obligation
to provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD, please see
the disclosure contained in our public filings with the Securities and Exchange
Commission, available on the Investors section of our website at
http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
Investor Inquiries:
iCAD Investor
Relations
[1]
Basic Information about Skin cancer. Centers for Disease Control. https://www.cdc.gov/cancer/skin/basic_info/index.htm
[2] Radiation:
Ultraviolet (UV) radiation and skin cancer. World Health Organization. https://www.who.int/news-room/questions-and-answers/item/radiation-ultraviolet-(uv)-radiation-and-skin-cancer